Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Sacco

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The British Journal of Oral & Maxillofacial Surgery|July 30, 2021
NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancersR C Brooker, A G Schache, J J Sacco
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 25, 2017
Modulating the DNA Damage Response to Improve Treatment Response in Cervical CancerL H Cossar, A G Schache, J M Risk, et al.
Oncogene|December 3, 2013
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cellsJ J Sacco, T Y Yau, S Darling, et al.
The British Journal of Oral & Maxillofacial Surgery|November 2, 2020
Adjuvant management of locally advanced oral squamous cell carcinoma - real-world challenges and opportunitiesR C Brooker, A Hobkirk, H Cashman, et al.
Journal of Comparative Pathology|August 1, 2018
Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine MelanomaN Jama, N Farquhar, Z Butt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The British Journal of Oral & Maxillofacial Surgery|July 30, 2021
NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancersR C Brooker, A G Schache, J J Sacco
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 25, 2017
Modulating the DNA Damage Response to Improve Treatment Response in Cervical CancerL H Cossar, A G Schache, J M Risk, et al.
Oncogene|December 3, 2013
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cellsJ J Sacco, T Y Yau, S Darling, et al.
The British Journal of Oral & Maxillofacial Surgery|November 2, 2020
Adjuvant management of locally advanced oral squamous cell carcinoma - real-world challenges and opportunitiesR C Brooker, A Hobkirk, H Cashman, et al.
Journal of Comparative Pathology|August 1, 2018
Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine MelanomaN Jama, N Farquhar, Z Butt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Pageof 1